Core Viewpoint - Nanjing Pharmaceutical Group Co., Ltd. plans to establish a subsidiary investment company focused on the medical device sector, with a significant investment from the company itself, aimed at enhancing its strategic positioning in the industry [1][2]. Group 1: Investment Structure - Nanjing Pharmaceutical will invest approximately 120 million yuan, accounting for 59.9% of the total registered capital of the new investment company [1]. - The investment company will be set up in collaboration with Nanjing New Industry Investment Management Co., Ltd. and Nanjing New Industry Medical Health Strong Chain M&A Equity Investment Fund [1]. Group 2: Target Investment - The newly formed investment company will specifically target an investment in Ningbo Jiangfeng Biological Information Technology Co., Ltd., acquiring approximately 22.5% of its equity, with a total valuation not exceeding 750 million yuan [2]. - Jiangfeng Biological, established in 2011, specializes in digital pathology and is recognized as a national high-tech enterprise focusing on innovative pathology diagnostics [2]. Group 3: Strategic Implications - The investment strategy reflects a model of "core enterprise + state-owned fund + industry chain target," which is expected to accelerate the transformation of technological achievements and promote innovation in the digital pathology field [2]. - This approach serves as a replicable example for local industrial development, encouraging collaboration between core enterprises and state-owned funds to enhance competitiveness and drive industrial upgrades [2].

Group 1 - The company held its fifth meeting of the tenth board of directors on December 18, 2025, with all nine directors present, and all resolutions were passed unanimously [3][6] - The company approved a proposal to invest CNY 119.8 million in establishing the Nanjing New Industry Medical Device Investment Company, which will focus on acquiring a 22.5% stake in Ningbo Jiangfeng Biological Information Technology Co., with a valuation cap of CNY 750 million [4][36] - The board authorized the management to handle all matters related to the investment and establishment of the medical device investment company [4][41] Group 2 - The company decided to change the purpose of repurchased shares from employee stock ownership plans to cancellation and reduction of registered capital, involving 39,852 shares [8][29] - The total share capital will decrease from 1,308,931,240 shares to 1,308,891,388 shares following the cancellation of the repurchased shares [9][34] - This change requires approval from the shareholders' meeting before implementation [29] Group 3 - The company announced that the convertible bonds issued on December 25, 2024, will start paying interest on December 25, 2025, with a coupon rate of 0.20% for the first year [13][21] - The total issuance amount of the convertible bonds is CNY 1,081.49 million, with a face value of CNY 100 per bond [14][15] - The bonds will have a conversion price of CNY 5.29 per share, which has been adjusted to CNY 5.12 [20] Group 4 - The company is participating in the establishment of the Nanjing New Industry Medical Device Investment Company, which is part of a broader strategy to enhance its investment in the healthcare sector [39][40] - The investment aligns with the company's strategic planning to extend its industrial chain and integrate resources in the healthcare industry [39][40] - The company aims to leverage social capital to improve the efficiency of fund utilization through this investment [39][40]

Core Viewpoint - Nanjing Pharmaceutical plans to invest 120 million yuan in a new equity investment company focused on the medical device sector, aiming to acquire a 22.5% stake in Ningbo Jiangfeng Biological Information Technology Co., Ltd, with a total valuation not exceeding 750 million yuan [1][2][3] Group 1: Investment Details - Nanjing Pharmaceutical will contribute 120 million yuan, representing 59.9% of the total capital of the newly established Nanjing New Industry Medical Device Investment Company [1] - The investment will specifically target Jiangfeng Biological, with the acquisition of approximately 22.5% equity based on a valuation cap of 750 million yuan [1][3] Group 2: Strategic Alignment - The investment aligns with Nanjing's municipal strategy to enhance industrial strength and integrate resources within the "2+6+6" innovative industrial system [2] - Nanjing Pharmaceutical's participation in this investment fund reflects its strategic plan to extend its existing industrial chain and embrace the "Health China" development strategy [2] Group 3: Target Company Overview - Jiangfeng Biological has over a decade of experience in the digital pathology industry and is recognized as a national high-tech enterprise focusing on innovative pathology diagnostics [3] - The company operates across five business segments, including digital pathology scanning systems and AI-assisted diagnostic systems, which complement Nanjing Pharmaceutical's digital transformation strategy [3]

Core Viewpoint - Nanjing Pharmaceutical plans to invest 120 million yuan in a new investment company focused on the medical device sector, specifically targeting a stake in Ningbo Jiangfeng Biological Information Technology Co., Ltd. [1][2] Group 1: Investment Details - Nanjing Pharmaceutical will hold a 59.9% stake in the newly established Nanjing XG South Medicine Medical Device Investment Company, which will focus on acquiring approximately 22.5% of Jiangfeng Biological at a valuation not exceeding 750 million yuan [1][2] - The investment aligns with Nanjing's municipal strategy to enhance industrial strength and integrate resources within the "2+6+6" innovative industrial system [2] Group 2: Strategic Alignment - The establishment of the investment fund is part of Nanjing Pharmaceutical's "14th Five-Year" strategic plan, which emphasizes the integration of health industry development and digital transformation [2] - The investment is expected to enhance the company's core competitiveness while extending its existing industrial chain [2] Group 3: Target Company Overview - Jiangfeng Biological has over a decade of experience in the digital pathology sector and is recognized as a national high-tech enterprise [3] - The company offers a comprehensive range of products and services, including digital pathology scanning systems and AI-assisted diagnostic systems, positioning it as a leader in the industry [3] - Jiangfeng's strong R&D capabilities and established market presence are expected to complement Nanjing Pharmaceutical's extensive business network and supply chain [3]